<?xml version='1.0' encoding='utf-8'?>
<document id="29569712"><sentence text="Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine."><entity charOffset="121-130" id="DDI-PubMed.29569712.s1.e0" text="Rifabutin" /><entity charOffset="134-147" id="DDI-PubMed.29569712.s1.e1" text="Carbamazepine" /><pair ddi="false" e1="DDI-PubMed.29569712.s1.e0" e2="DDI-PubMed.29569712.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29569712.s1.e0" e2="DDI-PubMed.29569712.s1.e1" /></sentence><sentence text="Rifampin demonstrated dose-dependent relative induction between cytochrome P (CYP)3A and P-glycoprotein (P-gp), organic anion transporting polypeptides (OATPs), or CYP2C9; P-gp, OATP, and CYP2C9 induction was one drug-drug interaction (DDI) category lower than that observed for CYP3A across a wide range of pregnane X receptor (PXR) agonism"><entity charOffset="0-8" id="DDI-PubMed.29569712.s2.e0" text="Rifampin" /></sentence><sentence text=" The objective of this study was to determine if these relationships could be utilized to predict transporter induction by other CYP3A inducers (rifabutin and carbamazepine) and of another P-gp substrate, sofosbuvir"><entity charOffset="145-154" id="DDI-PubMed.29569712.s3.e0" text="rifabutin" /><entity charOffset="159-172" id="DDI-PubMed.29569712.s3.e1" text="carbamazepine" /><entity charOffset="205-215" id="DDI-PubMed.29569712.s3.e2" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.29569712.s3.e0" e2="DDI-PubMed.29569712.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29569712.s3.e0" e2="DDI-PubMed.29569712.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29569712.s3.e0" e2="DDI-PubMed.29569712.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29569712.s3.e1" e2="DDI-PubMed.29569712.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29569712.s3.e1" e2="DDI-PubMed.29569712.s3.e2" /></sentence><sentence text=" Healthy subjects received sofosbuvir and a six-probe drug cassette before and after 300 mg q"><entity charOffset="27-37" id="DDI-PubMed.29569712.s4.e0" text="sofosbuvir" /></sentence><sentence text="d" /><sentence text=" rifabutin or 300 mg b"><entity charOffset="1-10" id="DDI-PubMed.29569712.s6.e0" text="rifabutin" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=" carbamazepine"><entity charOffset="1-14" id="DDI-PubMed.29569712.s9.e0" text="carbamazepine" /></sentence><sentence text=" Induction of P-gp, CYP2C9, and decreased sofosbuvir exposure were successfully predicted by observed CYP3A induction"><entity charOffset="42-52" id="DDI-PubMed.29569712.s10.e0" text="sofosbuvir" /></sentence><sentence text=" Carbamazepine induction of OATP was underpredicted, likely due to reported additional non-PXR agonism"><entity charOffset="1-14" id="DDI-PubMed.29569712.s11.e0" text="Carbamazepine" /></sentence><sentence text=" The results demonstrate that the effect of a PXR agonist on CYP3A can be leveraged to inform on induction liability for other primarily PXR-regulated P450s/transporters, allowing for prioritization of targeted DDI assessments during new drug development" /><sentence text="" /></document>